Are Wall Street Analysts Predicting Pfizer Stock Will Climb or Sink?

With a market cap of $161.3 billion, New York-based Pfizer Inc. (PFE) is a leading global biopharmaceutical company. Known for its innovative drugs and vaccines, it serves diverse therapeutic areas, including oncology, immunology, rare diseases, and infectious diseases.

Shares of Pfizer have significantly underperformed the broader market over the past 52 weeks. PFE stock has dipped 5.5% over this time frame, while the broader S&P 500 Index ($SPX) has rallied 41.7%. In 2024, shares of PFE are down 1.2%, compared to SPX's 22.3% gain on a YTD basis.